Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

National Immunization Strategy 2017-2022


Foreword
 
There have been many transformations to the NIP inthe recent years. New vaccines wereadded to the vaccination schedule, the cohorts served by the public sector kepton expandingsince the onset of the Syrian crisis, measures to consolidatethe vaccine purchasing arrangements were adopted,and there wasa leveraging up ofthe vaccinovigilanceand its effective management.In 2016, the Ministryof health in Lebanon decided that it was the time to take stock, constructon the current NIP strengthsand achievements andidentify areas for further improvement. A strategy for the NIP for 2016-2020 wasenvisagedin agreementwith the development partners. A detailed situation analysis assessment was initiatedin October 2015 in two stages: at the initial stage, the country and health system contexts were analyzed, and immunization system performance was measured. In the second stage, a framework was developed in consultations with key stakeholders to define gaps in the evidence. Immunization coverage evaluation survey was conducted in 2016 and fed into filling the lacunas in information.

The present document expresses the country vision, goals and priorities of the national immunization program. It relies on a careful examination of the situation analysis, an assessment of the enablers and challenges facing the immunization services and defines the national immunization strategies addressing these contests. The strategies were formulated as informed choices across more than one solution deemed most feasible and efficient considering the country context.

The document is structured in three sections:

Section 1“Situational analysis” presents briefly the organization and operation of the national immunization program as well as the recent achievements and remaining challenges,

Section 2 “Conceptual framework” describes the future vision of the country in regards to vaccine preventable diseases, the long term goals to be achieved and the more specific results –immunization system objectives and targets for 2020,

Section 3 defines the Strategies to address the bottlenecks and achieve immunization system objectives by 2020. Most of strategies (so called “immunization system specific” ones) are presented by relevant health system blocks.The focus of the NIP Strategy, is to assistthe MOPH to meet international goals set by the World Health Organization (WHO) under the Global Immunization Vision and Strategy (GIVS). The Strategy articulates action areas to conserve the successful achievements of the last years, built on the current favoring momentum and propose solutions for the drawbacks

The Strategy comprises nineStrategic Priority Areas to complement and strengthen the NIP.

The matrix (Figure 2) in Annexesshows expected results of the immunization system development strategies by health system building blocks and links them to the root causes (weaknesses and treats) identified during the system analysis...
    4
    ...
ATC Name B/G Ingredients Dosage Form Price
A02BC01 OMEPRAZOLE PHARMADEX G Omeprazole - 20mg 20mg Capsule 415,951 L.L
L01EF01 PALBOMED G Palbociclib - 100mg 100mg Capsule 23,911,751 L.L
M01AE01 DOLORAZ 400 G Ibuprofen - 400mg 400mg Capsule 295,645 L.L
N03AX16 PREGAFORTE 75 G Pregabalin - 75mg 75mg Capsule 793,507 L.L
A02BC01 OMEPRAZOLE PHARMADEX G Omeprazole - 20mg 20mg Capsule 15,757,784 L.L
A07EA06 BUDENOFALK B Budesonide - 3mg 3mg Capsule 8,554,692 L.L
L01EF01 PALBRANCE 100 G Palbociclib - 100mg 100mg Capsule 168,011,222 L.L
A02BC01 OMEZOL BENTA G Omeprazole - 20mg 20mg Capsule 550,336 L.L
N03AX16 GABRIKA 100 G Pregabalin - 100mg 100mg Capsule 798,626 L.L
A02BC01 OMEZOL BENTA G Omeprazole - 20mg 20mg Capsule 317,403 L.L
L01EF01 IBRANCE B Palbociclib - 125mg 125mg Capsule 172,164,216 L.L
N03AX16 PREGAFORTE 100 G Pregabalin - 100mg 100mg Capsule 998,283 L.L
N03AX16 GABRIKA 25 G Pregabalin - 25mg 25mg Capsule 560,062 L.L
A02BC01 SANAMIDOL G Omeprazole - 20mg 20mg Capsule 456,906 L.L
L01EF01 PALBOMED G Palbociclib - 125mg 125mg Capsule 25,799,521 L.L
M01AE01 ADVIL LIQUI-GELS EXTRA STRENGTH B Ibuprofen - 400mg 400mg Capsule 575,165 L.L
N03AX16 GABRIKA 25 G Pregabalin - 25mg 25mg Capsule 341,720 L.L
A02BC01 STOMAZOLE G Omeprazole - 20mg 20mg Capsule 593,850 L.L
L01EF01 PALBRANCE 125 G Palbociclib - 125mg 125mg Capsule 69,032,469 L.L
N03AX16 NEUREXAL G Pregabalin - 25mg 25mg Capsule 321,754 L.L
A02BC01 STOMAZOLE G Omeprazole - 20mg 20mg Capsule 15,757,784 L.L
N03AX16 PLENICA G Pregabalin - 25mg 25mg Capsule 697,454 L.L
J07AX URO-VAXOM B Lyophilized bacterial lysates of E-Coli - 6mg 6mg Capsule 2,689,029 L.L
N02AJ13 ALGODOL G Paracetamol - 325mg, Tramadol HCl - 37.5mg Capsule 317,403 L.L
N03AX16 PMS-PREGABALIN G Pregabalin - 25mg 25mg Capsule 770,022 L.L
J07AX BRONCHO-VAXOM CHILDREN B Lyophilized bacterial lysates of Haemophilus influenzae, Diplococcus pneumoniae, Klebsiella pneumoniae and ozaenae, Staphylococcus aureus, Streptococcus pyogenes and viridans, Neisseria catarrhalis - 3.5mg Capsule 1,988,887 L.L
N03AX16 PREGAFORTE 25 G Pregabalin - 25mg 25mg Capsule 700,078 L.L
J07AX BRONCHO-VAXOM ADULTS B Lyophilized bacterial lysates of Haemophilus influenzae, Diplococcus pneumoniae, Klebsiella pneumoniae and ozaenae, Staphylococcus aureus, Streptococcus pyogenes and viridans, Neisseria catarrhalis - 7mg Capsule 2,746,814 L.L
N06AB06 SERTRALINE BIOGARAN G Sertraline HCl - 50mg 50mg Capsule 520,067 L.L
N02AX02 TRAMAL B Tramadol HCl - 50mg 50mg Capsule 349,399 L.L
    4
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025